Abstract
In this pharmacoeconomic simulation, we: (1) modeled the cost-efficiency of converting patients from reference pegfilgrastim to biosimilar pegfilgrastim-cbqv for prophylaxis of chemotherapy-induced...
Funding Information
  • Coherus BioSciences, Inc.

This publication has 32 references indexed in Scilit: